DUB-IN-3

An inhibitor of USB8 (IC50 = 0.56 µM); selective for USP8 over USP7 (IC50 = >100 µM); an inhibitor of SARS-CoV-2 PLpro when Z-LRGG-AMC is used as a substrate (IC50 = 12.5 µM) but not when Ub-AMC is used as a substrate (IC50 = >10 µM); reduces GSH levels and cystine uptake, as well as increases ferrous iron and ROS levels, in HCCLM3 cells at 0.2 or 0.5 µM; decreases viability of HCCLM3 cells when used with RSL3, an effect that can be blocked by ferrostatin-1; reduces the proliferation, migration, and oncosphere formation ability of HCCLM3 and Hep3B hepatocellular carcinoma cells at 0.1 and 0.2 µM; reduces tumor growth and metastasis in HCCLM3 and Hep3B mouse models of metastatic lung cancer at 5 mg/kg per day